Elite 50% OFF Act now – get top investing tools Register Now!

MaxCyte, Inc

Contributing Author

Recent Articles by MaxCyte, Inc

Nov-12	MaxCyte Announces Planned CFO Transition in 2026 MXCT GlobeNewswire
Nov-12	MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Nov-05	MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Oct-08	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 MXCT GlobeNewswire
Oct-06	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MXCT GlobeNewswire
Sep-22	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability MXCT GlobeNewswire
Aug-06	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance MXCT GlobeNewswire
Aug-04	MaxCyte Signs Platform License Agreement with Adicet Bio MXCT GlobeNewswire
Jul-31	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline MXCT GlobeNewswire
Jul-09	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 MXCT GlobeNewswire
Jun-11	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies MXCT GlobeNewswire
May-07	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT GlobeNewswire
May-07	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.